AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

STARPHARMA HOLDINGS LTD

0.785

-0.025-3.09%

Volume:1.91M

Turnover:1.53M

Market Cap:374.49M

PE:-46.18

High:0.830

Open:0.805

Low:0.785

Close:0.810

52wk High:0.830

52wk Low:0.112

Shares:477.05M

Float Shares:347.84M

Volume Ratio:0.94

T/O Rate:0.55%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.017

EPS(LYR):-0.020

ROE:-45.55%

ROA:-21.00%

PB:27.18

PE(LYR):-39.25

Loading ...

Overview Company News Filings

ASX Growth Leaders With High Insider Stakes

Simply Wall St.

ASX Growth Leaders With High Insider Ownership April 2026

Simply Wall St.

ASX Growth Companies With High Insider Ownership April 2026

Simply Wall St.

Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%

MT Newswires Live

Starpharma plans first-in-human Phase 1 trial of DEP HER2 radiotherapy in Europe

Starpharma Holdings Ltd-FDA Confirms Path to Dep Her2 First-in-Human Study

THOMSON REUTERS

Rhuroin becomes Starpharma substantial holder with 9.52% stake

ASX Penny Stocks To Watch In April 2026

Simply Wall St.

$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

2 ASX small-cap shares with 100% potential upside

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/SPL.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SPL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SPL.AU\",,,,,undefined,":{"symbol":"SPL.AU","market":"AU","secType":"STK","nameCN":"STARPHARMA HOLDINGS LTD","latestPrice":0.785,"timestamp":1789020720000,"preClose":0.81,"halted":0,"volume":1914746,"delay":0,"changeRate":-0.030864197530864224,"nameEN":"STARPHARMA HOLDINGS LTD","floatShares":347835291,"shares":477054949,"eps":-0.017,"marketStatus":"Not Yet Opened","change":-0.025,"latestTime":"09-10 16:12:00 AEST","open":0.805,"high":0.83,"low":0.785,"amount":1528905,"amplitude":0.055556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.017,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.81,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":0.9408682885019167,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"SPL.AU","preClose":0.81,"auctionPrice":0.785,"auctionVolume":158277,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020603562}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SPL.AU\",,,,,undefined,":{"symbol":"SPL.AU","floatShares":347835291,"roa":"-21.00%","roe":"-45.55%","lyrEps":-0.02,"volumeRatio":0.9408682885019167,"shares":477054949,"dividePrice":0,"high":0.83,"amplitude":0.055556,"preClose":0.81,"low":0.785,"week52Low":0.112,"pbRate":"27.18","psRate":"29.56","week52High":0.83,"institutionHeld":0,"latestPrice":0.785,"eps":-0.017,"divideRate":0,"volume":1914746,"delay":0,"ttmEps":-0.017,"open":0.805,"prevYearClose":0.351,"prevWeekClose":0.755,"prevMonthClose":0.72,"prevQuarterClose":0.682,"fiveDayClose":0.735,"twentyDayClose":0.725,"sixtyDayClose":0.682},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPL.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-07-17","symbol":"SPL.AU","defaultRemindTime":1784246400000,"type":"split","dateTimestamp":1784210400000,"forFactor":974214,"toFactor":1000000,"ratio":0.974214}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPL.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPL.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630010343","title":"ASX Growth Leaders With High Insider Stakes","url":"https://stock-news.laohu8.com/highlight/detail?id=2630010343","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630010343?lang=en_us&edition=fundamental","pubTime":"2026-04-28 03:08","pubTimestamp":1777316908,"startTime":"0","endTime":"0","summary":"As the Australian Securities Exchange (ASX) seeks stability following a soft week, investors are keenly observing global market trends and geopolitical events that could influence local market sentiment. In such an environment, growth companies with high insider ownership can be particularly appealing, as insiders' stakes often signal confidence in the company's potential amidst fluctuating economic conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-frs/forrestania-resources-shares/news/asx-growth-leaders-with-high-insider-stakes-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-frs/forrestania-resources-shares/news/asx-growth-leaders-with-high-insider-stakes-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ASX.AU","BK7039","XAO.AU","IMA.AU","BK7508","BK7016","SKS.AU","EIQ.AU","BK7110","BK4543","TOR.AU","ASX","BK7104","SPL.AU","XJO.AU","XKO.AU","BK7501","BK7036","MAU.AU","BK4141","BK7017","BK7095","AV1.AU","FRS.AU","AR1.AU","BK7062","BK4526","AEM.AU","BK7023","BK7096","TTT.AU","PNI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331928","title":"ASX Growth Leaders With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331928","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331928?lang=en_us&edition=fundamental","pubTime":"2026-04-27 03:08","pubTimestamp":1777230494,"startTime":"0","endTime":"0","summary":"As the Australian share market shows resilience with a +0.4% advance amidst global uncertainties, particularly contrasting Wall Street's downturn, investors are keenly observing how local factors such as potential interest rate changes influence trading sentiment. In this environment, companies with high insider ownership often attract attention for their perceived alignment of interests between management and shareholders, making them notable candidates for those seeking growth opportunities...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-leaders-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XKO.AU","IMA.AU","BK7095","XAO.AU","BK4139","BK7036","REG.AU","AR1.AU","BK7096","BK7016","BK7506","TLX.AU","XJO.AU","SKS.AU","AMI.AU","EIQ.AU","TTT.AU","BK7104","BK7067","FRS.AU","BK7501","BK7113","AV1.AU","TOR.AU","BK7110","BK7508","BK7023","SPL.AU","MAU.AU","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629502869","title":"ASX Growth Companies With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629502869","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629502869?lang=en_us&edition=fundamental","pubTime":"2026-04-24 03:08","pubTimestamp":1776971318,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a complex landscape marked by geopolitical tensions and fluctuating commodity prices, investors are keeping a close eye on growth companies with high insider ownership. In such an environment, stocks with significant insider stakes can be appealing due to the potential alignment of interests between company leaders and shareholders, offering a sense of confidence amidst global uncertainties.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-companies-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-companies-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7141","LTR.AU","BK7104","BK7143","BK7110","BK7023","SKS.AU","FRS.AU","AV1.AU","TTT.AU","BK7016","BK7095","BK7067","BK7508","BK7501","ASG.AU","CUV.AU","XAO.AU","BK7096","BK7036","CBO.AU","BK7504","IMA.AU","TOR.AU","AR1.AU","XKO.AU","MAU.AU","SPL.AU","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706213","title":"Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706213","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706213?lang=en_us&edition=fundamental","pubTime":"2026-04-21 11:15","pubTimestamp":1776741344,"startTime":"0","endTime":"0","summary":"Starpharma Holdings  has received positive feedback from the US Food and Drug Administration  on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","LABU","BK4588","SPL.AU","BK7501","BK4585","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629127772","title":"Starpharma plans first-in-human Phase 1 trial of DEP HER2 radiotherapy in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2629127772","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629127772?lang=en_us&edition=fundamental","pubTime":"2026-04-21 07:43","pubTimestamp":1776728625,"startTime":"0","endTime":"0","summary":"Starpharma received positive FDA feedback in a Type C guidance meeting on proposed first-in-human Phase 1 strategy for DEP HER2 radiotherapy candidate DEP HER21.Company plans to start trial in H2 2026 in Europe, targeting up to 15 patients with advanced HER2-expressing cancers.Study will assess safety and tolerability, aiming to support later US development under an IND.No trial results have been presented; initial clinical data are expected once first-in-human study is underway.FDA feedback also supported potential use of accelerated pathways in future, citing significant unmet need in patients who have exhausted HER2-directed therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Starpharma Holdings Limited published the original ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL5hB2jx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","SPL.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629772971","title":"Starpharma Holdings Ltd-FDA Confirms Path to Dep Her2 First-in-Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629772971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629772971?lang=en_us&edition=fundamental","pubTime":"2026-04-21 07:40","pubTimestamp":1776728413,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUE3VCJTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","BK7501","SPL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420841","title":"Rhuroin becomes Starpharma substantial holder with 9.52% stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420841","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420841?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:46","pubTimestamp":1776206771,"startTime":"0","endTime":"0","summary":"Rhuroin became a substantial holder in Starpharma on April 13, 2026.Holding totals 40,050,000 ordinary shares, equal to 9.52% voting power.Filing lists Rhuroin as beneficial owner of the stake.Disclosure shows cash consideration of 12,195,674 for 33,646,180 shares acquired within prior four months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Starpharma Holdings Limited published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL3DTXgD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7096","SPL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625994832","title":"ASX Penny Stocks To Watch In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625994832","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625994832?lang=en_us&edition=fundamental","pubTime":"2026-04-08 10:05","pubTimestamp":1775613911,"startTime":"0","endTime":"0","summary":"As the Australian share market navigates through a period of geopolitical uncertainty, with futures showing resilience despite global tensions, investors are keeping a keen eye on potential opportunities. Penny stocks, often seen as relics from past market eras, continue to offer intriguing possibilities for those looking beyond the mainstream. These smaller or newer companies can provide growth potential and affordability when backed by strong financials, making them an area worth exploring.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/7131000-choice1-main-header/1585186655666","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7131000-choice1-main-header/1585186655666"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-amh/amcil-shares/news/asx-penny-stocks-to-watch-in-april-2026-4","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-amh/amcil-shares/news/asx-penny-stocks-to-watch-in-april-2026-4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EDU.AU","KCN.AU","BK7088","BK7016","BK7508","CLX.AU","CGS.AU","WAF.AU","PPS.AU","LBL.AU","BK7062","BK7503","BK7132","SSG.AU","BK7104","AEF.AU","BK7506","AMH.AU","BK7501","BK7094","BK7096","BK7128","OBM.AU","SPL.AU","RPL.AU","BK7058"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622188031","title":"$10,000 invested in this ASX healthcare share a year ago is now worth $36,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2622188031","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622188031?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:53","pubTimestamp":1774497205,"startTime":"0","endTime":"0","summary":"ASXhealthcare share Starpharma Holdings Ltd  has rocketed 365% over the past 12 months.Had you put $10,000 into this ASXsmall-capshare in March 2025, your holdings would be worth $36,500 today.These nanoscale molecules make medicines more effective in the body.Starpharma licenses its drug delivery technology to large pharma, and also develops its own anti-infection products.This ASX healthcare share is trading at 47 cents on Thursday, up 1.1%.What's behind the dramatic 365% share price rise?In September, the ASX healthcare share rose by more than 100% after the company announced two new partnerships.Starpharma signed a research and option agreement with Radiopharm Theranostics Ltd that made it eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based payments and royalties on net sales.Is it too late to buy this rising ASX healthcare share?ASX biotech shares are notoriously risky and unsuitable for investors with a low risk toleranc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4585","BK4588","BK7067","BK7096","SPL.AU","BK4550","BK7501","VHT","BK7508","IXJ","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619166851","title":"2 ASX small-cap shares with 100% potential upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2619166851","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619166851?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:49","pubTimestamp":1773384550,"startTime":"0","endTime":"0","summary":"TheS&P/ASX Small Ords Index is down 0.1% on Friday but up 16% over the past 12 months.By comparison, the S&P/ASX All Ords Index is up 0.07% today and has risen 11% over the past year.The Small Ords index tracks ASX companies ranked 101-300 by market capitalisation. The ASX All Ords tracks the top 500.ASX small-cap sharestypically have market caps between a few hundred million dollars and $2 billion.Here are two ASX small-cap shares that the experts rate as buys, with a potential upside of 100% each over the next 12 months.PAC Partners has a buy rating on this ASX small-cap healthcare share.PAC Partners says it has a \"high risk\" 12-month price target of between 80 cents and $1 on this ASX small-cap share.Starpharma Holdings Limited  will start human clinical trials of its novel radiotherapy drug for a solid cancer target by the end of 2026.This ASX small-cap share is trading for 21 cents, down 4.55% today and up 147% over the past 12 months.RaaS Advisory, which specialises in small-cap ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/13/2-asx-small-cap-shares-with-100-potential-upside/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/13/2-asx-small-cap-shares-with-100-potential-upside/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","XAO.AU","SPL.AU","BK7096","VBC.AU","BK7055","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":70,"code":"91000000","status":"200"}]}}